List of Research Topics for the Early Part of May Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Glatiramer acetate after induction therapy with   more »

The neuropathology of multiple sclerosis is characterised by focal damage to white matter. However, tissue damage is also present in the cortical grey matter, with a particularly high   more »

is generally a lifelong condition for which there is no cure. Symptoms may gradually worsen with age, though more slowly for those   more »

There is a single clinical trial of MS that evaluated magnets for MS-related cognitive dysfunction. That trial, which involved 30 people, evaluated cognition as one part of a battery of tests that also measured spasticity, bladder control, fatigue, mobility   more »

Currently, there is no single diagnostic test for RLS. The disorder is diagnosed clinically by evaluating the patient's history and symptoms. Despite a clear description of clinical features, the condition   more »

Combination therapies in multiple sclerosis.

 

 

 The last years have seen enormous progress in our understanding of pathophysiology (1) of multiple sclerosis. In addition, the armamentarium (2) of available immunomodulatory or immunosuppressive therapies (3) has greatly increased, especially for the relapsing remitting form of the disease.

 

Since their therapeutic efficacy is often limited in individual patients, it is conceivable that combination therapies may bring improved clinical efficacy while managing increasing side effects and toxicity. The combination of agents with additive or synergistic modes of action is of particular interest. Combination of the two classes of recognised first-line treatment, a beta-interferon and glatiramer acetate is currently under evaluation in a large Phase III trial.

 

However, there are theoretical reasons for thinking that such a combination may not be particularly beneficial. None of the combination studies performed with beta-interferons to date have shown unequivocal evidence of benefit, including combinations with statins, natalizumab, and azathioprine.

 

On the other hand, for glatiramer acetate, the combination with mitoxantrone used as induction therapy may be of interest and preliminary data on combination with minocycline are also promising.

 

University of Bochum,

St. Josef-Hospital,

Dept. of Neurology,

Gudrunstr. 56, 44791,

Bochum, Germany.

 

 

Terms:

1. pathophysiology - The study of such changes.
2. Armamentarium - the equipment and materials of the clinician
3. - immunomodulatory agents that alter the immune response by suppression or enhancement

In small studies, cooling techniques, or lowering the body temperature, has been reported to improve multiple symptoms among people with MS. In one such small study of eight patients, an improvement was seen in one patient’s ability to   more »

Multiple sclerosis is a lifelong, immune-mediated progressive disorder. The early age of onset and the chronic nature of the disease with accumulation of physical disability, demand a long-term ("lifelong") management, including   more »

As described above, people with RLS feel uncomfortable sensations in their legs, especially when sitting or lying down, accompanied by an irresistible urge to move about. These sensations   more »

Restless legs syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and an uncontrollable urge to move when   more »

List of Upcoming Articles regarding Restless Leg Syndrome

 

  1.  What Restless Leg Syndrome is

  2.  What are common signs and symptoms of restless legs?

  4.  What causes restless legs syndrome?

  5.  How is restless legs syndrome diagnosed?

  6.  How is restless legs syndrome treated?

  7.  What is the prognosis of people with restless legs?

  8.  What research is being done?

  9.  Study of Pramipexole presented at AAN

10.  Drug Information: Pramipexole

11.  Where can I get more information?

12.  Health Canada Warnings of Dietary Supplements for RLS

Below; is the number of total visitors as of: April 26, 2008: ¯¯¯   more »

The ELR+ CXC chemokines CXCL1 and CXCL2 are up-regulated in the central nervous system (CNS) during multiple sclerosis (MS) and its animal model, experimental autoimmune   more »

Pemoline belongs to the group of medicines called central nervous system (CNS) stimulants. It is used to treat children with attention-deficit hyperactivity disorder (ADHD). Pemoline increases attention and decreases restlessness in   more »

There is a large and growing body of evidence to support the idea that a lifetime of exercise can result in preservation of a number of aspects of cognition. Much of this literature has focused on aerobic exercise such as walking, running, bicycling   more »